Danish dermatology specialist Leo Pharma has scored an FDA approval that makes its JAK inhibitor cream Anzupgo (del | Despite chronic hand eczema affecting 1 in 10 people worldwide, there was no ...

LEO Pharma’s Anzupgo (delgocitinib) cream has been approved by the US Food and Drug Administration (FDA) to treat adults with ...

LEO Pharma Inc. announced today that the Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream for ...

Ballerup, Denmark Saturday, July 26, 2025, 15:00 Hrs [IST] ...

The FDA approved Anzupgo for the treatment of moderate to severe chronic hand eczema in adults who do not adequately respond ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

The FDA has approved a new treatment, sold under the name Anzupgo and containing a drug called delgocitinib, as the first skin cream for adults with long-term or chronic hand eczema (CHE), which ...

Privately-held Danish dermatology specialist LEO Pharma today revealed that the US Food and Drug Administration (FDA) has ...

LEO Pharma has announced that its Anzupgo (delgocitinib) cream has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat chronic hand eczema (CHE). The treatment has ...

The first therapy specifically indicated for chronic hand eczema (CHE) has passed muster at the FDA.

The U.S. Food and Drug Administration (FDA) has signed off on the first-ever cream specifically approved for treating chronic ...